Synopsis
0
EU WC
0
KDMF
0
VMF
0
FDF
0
FDA Orange Book
0
Europe
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Arginine Hydrochloride
2. Arginine, L Isomer
3. Arginine, L-isomer
4. Dl Arginine Acetate, Monohydrate
5. Dl-arginine Acetate, Monohydrate
6. Hydrochloride, Arginine
7. L Arginine
8. L-arginine
9. L-isomer Arginine
10. Monohydrate Dl-arginine Acetate
1. L-arginine
2. 74-79-3
3. L-(+)-arginine
4. L(+)-arginine
5. L-arg
6. (s)-2-amino-5-guanidinopentanoic Acid
7. H-arg-oh
8. (l)-arginine
9. Arginina
10. Arginine, L-
11. Arginine (van)
12. L-arginin
13. Argininum [inn-latin]
14. Arginina [inn-spanish]
15. L-ornithine, N5-(aminoiminomethyl)-
16. Argamine
17. Argivene
18. Detoxargin
19. Levargin
20. L-alpha-amino-delta-guanidinovaleric Acid
21. Arg
22. Minophagen A
23. 1-amino-4-guanidovaleric Acid
24. Ccris 3609
25. (s)-(+)-arginine
26. Nsc 206269
27. Chebi:16467
28. Hsdb 1429
29. Ai3-24165
30. (s)-2-amino-5-((aminoiminomethyl)amino)pentanoic Acid
31. (s)-2-amino-5-guanidinovaleric Acid
32. Brn 1725413
33. L-norvaline, 5-((aminoiminomethyl)amino)-
34. 2-amino-5-guanidinovaleric Acid
35. Chembl1485
36. (2s)-2-amino-5-guanidinopentanoic Acid
37. (s)-2-amino-5-[(aminoiminomethyl)amino]pentanoic Acid
38. (2s)-2-amino-5-(diaminomethylideneamino)pentanoic Acid
39. 94zla3w45f
40. Pentanoic Acid, 2-amino-5-((aminoiminomethyl)amino)-, (s)-
41. (2s)-2-amino-5-(carbamimidamido)pentanoic Acid
42. L-arginine, Monohydrochloride
43. Nsc-206269
44. Arginine (l-arginine)
45. R-gene
46. L-norvaline, 5-[(aminoiminomethyl)amino]-
47. (2s)-2-amino-5-carbamimidamidopentanoic Acid
48. Dsstox_cid_21056
49. Dsstox_rid_79618
50. Dsstox_gsid_41056
51. Argininum
52. Pentanoic Acid, 2-amino-5-[(aminoiminomethyl)amino]-, (s)-
53. Arginine [usan:inn]
54. Cas-74-79-3
55. Arginine [usp:inn]
56. Einecs 200-811-1
57. Mfcd00002635
58. 2-amino-5-guanidino-pentanoic Acid
59. Unii-94zla3w45f
60. Nsc203450
61. 3h-l-arginine
62. L-arginine, Labeled With Tritium
63. 1laf
64. L-a-amino-d-guanidinovaleric Acid
65. Ncgc00015064-02
66. (s)-arginine
67. L(+) Arginine
68. L-aryginine,(s)
69. H-arg
70. L-(+) Arginine
71. L(+)-arginine;
72. L-arginine (9ci)
73. Arginine (usp/inn)
74. Tocris-0663
75. (2s)-2-amino-5-guanidino-pentanoic Acid
76. Arginine [hsdb]
77. Arginine [inci]
78. L-arginine (jp17)
79. Arginine [inn]
80. Arginine [ii]
81. Arginine [mi]
82. Arginine [vandf]
83. Gnd
84. Lopac-a-5006
85. Arginine, L- (8ci)
86. Arginine [mart.]
87. L-arginine [fcc]
88. L-arginine [jan]
89. Arginine [who-dd]
90. Bmse000029
91. Bmse000899
92. Bmse000919
93. Epitope Id:140084
94. L-arginine (h-arg-oh)
95. L-arginine [fhfi]
96. Ec 200-811-1
97. Schembl1791
98. 2-amino-5-guanidinovalerate
99. Lopac0_000077
100. Arginine Hydrochloride(usan)
101. Gtpl721
102. L-arginine [usp-rs]
103. 4-04-00-02648 (beilstein Handbook Reference)
104. L-a-amino-d-guanidinovalerate
105. L-amino-4-guanidovaleric Acid
106. Arginine [ep Impurity]
107. Us9138393, L-arginine
108. Us9144538, L-arginine
109. 1-amino-4-guanidovalerlic Acid
110. Arginine [ep Monograph]
111. Arginine [usp Monograph]
112. Dtxsid6041056
113. Bdbm21959
114. L-arginine, 99%, Fcc, Fg
115. Bdbm181132
116. Hms3260o15
117. N5-(aminoiminomethyl)-l-ornithine
118. Hy-n0455
119. Zinc1532525
120. L-arginine, Vetec(tm), 98.5%
121. Tox21_113046
122. Tox21_500077
123. Ac-083
124. L-2-amino-5-guanidinopentanoic Acid
125. L-alpha-amino-delta-guanidinovalerate
126. L-arginine, Reagent Grade, >=98%
127. S5634
128. Akos006239069
129. Akos015854096
130. Tox21_113046_1
131. Am81500
132. Ccg-204172
133. Db00125
134. Lp00077
135. Sdccgsbi-0050065.p002
136. L-arginine, 99%, Natural, Fcc, Fg
137. (s)-2-amino-5-guanidino-pentanoic Acid
138. 5-[(aminoiminomethyl)amino]-l-norvaline
139. Ncgc00015064-01
140. Ncgc00024715-01
141. Ncgc00024715-02
142. Ncgc00024715-03
143. Ncgc00024715-04
144. Ncgc00024715-05
145. Ncgc00024715-10
146. Ncgc00260762-01
147. 4455-52-1
148. As-14190
149. L-arginine, Bioultra, >=99.5% (nt)
150. Sbi-0207062.p001
151. A0526
152. A7079
153. Eu-0100077
154. L-arginine, Saj Special Grade, >=98.0%
155. A 5006
156. C00062
157. D02982
158. L-arginine, Vetec(tm) Reagent Grade, >=98%
159. Lysine Acetate Impurity F [ep Impurity]
160. M02981
161. 2-azaniumyl-5-(diaminomethyleneammonio)pentanoate
162. Ab00374192_03
163. Norvaline, 5-[(aminoiminomethyl)amino]-, (l)-
164. 002a635
165. A837397
166. A929348
167. Q173670
168. Sr-01000075479
169. Sr-01000597671
170. (s)-2-amino-5-[(aminoiminomethyl)amino]-pentanoate
171. (s)-2-amino-5-[(aminoiminomethyl)amino]pentanoate
172. Sr-01000075479-1
173. Sr-01000597671-1
174. W-104410
175. (s)-2-amino-5-[(aminoiminomethyl)amino]-pentanoic Acid
176. Arginine, European Pharmacopoeia (ep) Reference Standard
177. (2s)-2-amino-5-[(diaminomethylidene)amino]pentanoic Acid
178. 7f15b0c7-356d-45d7-ac33-03aee4394a0e
179. S-(+)-2-amino-5-[(aminoiminomethyl)amino]pentanoic Acid
180. (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic Acid
181. L-arginine, United States Pharmacopeia (usp) Reference Standard
182. L-arginine, Pharmaceutical Secondary Standard; Certified Reference Material
183. L-
184. L-arginine, From Non-animal Source, Meets Ep, Usp Testing Specifications, Suitable For Cell Culture, 98.5-101.0%
185. L-arginine, Pharmagrade, Ajinomoto, Ep, Usp, Manufactured Under Appropriate Gmp Controls For Pharma Or Biopharmaceutical Production, Suitable For Cell Culture
1. L-arginine
| Molecular Weight | 174.20 g/mol |
|---|---|
| Molecular Formula | C6H14N4O2 |
| XLogP3 | -4.2 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 5 |
| Exact Mass | 174.11167570 g/mol |
| Monoisotopic Mass | 174.11167570 g/mol |
| Topological Polar Surface Area | 128 Ų |
| Heavy Atom Count | 12 |
| Formal Charge | 0 |
| Complexity | 176 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | R-gene 10 |
| Active Ingredient | Arginine hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 10gm/100ml |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
| 2 of 2 | |
|---|---|
| Drug Name | R-gene 10 |
| Active Ingredient | Arginine hydrochloride |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 10gm/100ml |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
EXPTL USE: IN MICE, L-ARGININE-HCL HAD AN INHIBITORY EFFECT ON MURINE SARCOMA VIRUS-MOLONEY & C3H BREAST ADENOCARCINOMA TUMOR SYSTEMS.
CRITSELIS AN ET AL; L-ARGININE INCREASES RESISTANCE TO TUMORS; CURR CHEMOTHER PROC INT CONGR CHEMOTHER, 10TH, VOL 2, 1978, 1122-4
EXPTL USE: EXPTL DIETS GIVEN 10 DAYS AFTER WALKER 256 CARCINOSARCOMA CELLS INOCULATED INTO RATS, RESULTED IN LOWER TUMOR WEIGHTS.
TAKAMURA C; INHIBITORY EFFECT OF ARGININE-SUPPLEMENTED DIETS ON GROWTH OF WALKER 256 CARCINOSARCOMA; KANSAI IKA DAIGAKU ZASSHI 29(3) 519 (1977)
EXPTL USE: L-ARGININE-HCL INCR IN VITRO MOTILITY IN SPECIMENS OF HUMAN SEMEN EXHIBITING SUBNORMAL MOTILITY. EFFECT WAS DOSE DEPENDENT.
KELLER DW ET AL; L-ARGININE STIMULATION OF HUMAN SPERM MOTILITY IN VITRO; BIOL REPROD 13(2) 154 (1975)
EXPTL USE: ARGININE (1% IN DIET) GIVEN TO RATS INCR THYMIC SIZE & PREVENTED THYMIC INVOLUTION WHICH OCCURS WITH INJURY. ARGININE PROMOTED WOUND HEALING IN RATS.
BARBUL A ET AL; ARGININE: A THYMOTROPIC & WOUND-HEALING PROMOTING AGENT; SURG FORUM 28: 101 (1977)
For more Therapeutic Uses (Complete) data for (L)-ARGININE (6 total), please visit the HSDB record page.
Used for nutritional supplementation, also for treating dietary shortage or imbalance.
Studies have shown that is has improved immune responses to bacteria, viruses and tumor cells; promotes wound healing and regeneration of the liver; causes the release of growth hormones; considered crucial for optimal muscle growth and tissue repair.
Absorption
Absorbed from the lumen of the small intestine into the enterocytes. Absorption is efficient and occurs by an active transport mechanism.
Some metabolism of L-arginine takes place in the enterocytes. L-arginine not metabolized in the enterocytes enters the portal circulation from whence it is transported to the liver, where again some portion of the amino acid is metabolized.
PRODUCT OF OXIDATIVE DEAMINATION OR TRANSAMINATION OF L-ARGININE IS ALPHA-KETO-GAMMA-GUANIDOVALERIC ACID; PRODUCT OF DECARBOXYLATION IS AGMATINE. PATHWAYS & PRODUCTS OF METABOLISM: ARGININE YIELDS ORNITHINE + UREA; ARGININE YIELDS CITRULLINE + NH3; ARGININE + GLYCINE YIELDS GUANIDOACETIC ACID + ORNITHINE /FROM TABLE/
Fenaroli's Handbook of Flavor Ingredients. Volume 2. Edited, translated, and revised by T.E. Furia and N. Bellanca. 2nd ed. Cleveland: The Chemical Rubber Co., 1975., p. 829
Many of supplemental L-arginine's activities, including its possible anti-atherogenic actions, may be accounted for by its role as the precursor to nitric oxide or NO. NO is produced by all tissues of the body and plays very important roles in the cardiovascular system, immune system and nervous system. NO is formed from L-arginine via the enzyme nitric oxide synthase or synthetase (NOS), and the effects of NO are mainly mediated by 3,'5' -cyclic guanylate or cyclic GMP. NO activates the enzyme guanylate cyclase, which catalyzes the synthesis of cyclic GMP from guanosine triphosphate or GTP. Cyclic GMP is converted to guanylic acid via the enzyme cyclic GMP phosphodiesterase. NOS is a heme-containing enzyme with some sequences similar to cytochrome P-450 reductase. Several isoforms of NOS exist, two of which are constitutive and one of which is inducible by immunological stimuli. The constitutive NOS found in the vascular endothelium is designated eNOS and that present in the brain, spinal cord and peripheral nervous system is designated nNOS. The form of NOS induced by immunological or inflammatory stimuli is known as iNOS. iNOS may be expressed constitutively in select tissues such as lung epithelium. All the nitric oxide synthases use NADPH (reduced nicotinamide adenine dinucleotide phosphate) and oxygen (O2) as cosubstrates, as well as the cofactors FAD (flavin adenine dinucleotide), FMN (flavin mononucleotide), tetrahydrobiopterin and heme. Interestingly, ascorbic acid appears to enhance NOS activity by increasing intracellular tetrahydrobiopterin. eNOS and nNOS synthesize NO in response to an increased concentration of calcium ions or in some cases in response to calcium-independent stimuli, such as shear stress. In vitro studies of NOS indicate that the Km of the enzyme for L-arginine is in the micromolar range. The concentration of L-arginine in endothelial cells, as well as in other cells, and in plasma is in the millimolar range. What this means is that, under physiological conditions, NOS is saturated with its L-arginine substrate. In other words, L-arginine would not be expected to be rate-limiting for the enzyme, and it would not appear that supraphysiological levels of L-arginine which could occur with oral supplementation of the amino acid^would make any difference with regard to NO production. The reaction would appear to have reached its maximum level. However, in vivo studies have demonstrated that, under certain conditions, e.g. hypercholesterolemia, supplemental L-arginine could enhance endothelial-dependent vasodilation and NO production.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
